Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US-2016207939-A1 · Jul 21, 2016 · US
Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity
US11267823B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11267823-B2 |
| Application number | US-202016924390-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 9, 2020 |
| Priority date | Apr 28, 2005 |
| Publication date | Mar 8, 2022 |
| Grant date | Mar 8, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the formula: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of claim 1 , or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of claim 1 . 4. A compound of the formula: 5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of claim 4 . 6. A compound of the formula: or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of claim 6 , or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of claim 6 . 9. A compound of the formula: 10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of claim 9 .
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
- C07D471/14Primary
Ortho-condensed systems · CPC title
- C07D498/14Primary
Ortho-condensed systems · CPC title
- A61K31/4985Primary
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11267823B2 cover?
- Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
- Who is the assignee on this patent?
- Shionogi & Co, Viiv Healthcare Co
- What technology area does this patent fall under?
- Primary CPC classification C07D471/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).